ARA-290

Overview

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the "tissue-protective" tertiary structure of erythropoietin (EPO) — designed specifically to retain EPO's tissue-protective signaling while removing the blood-cell-stimulating (erythropoietic) activity that makes native EPO risky to administer chronically.

Proposed Mechanism of Action

ARA-290 is proposed to act on the "innate repair receptor" (a heterodimer of the EPO receptor and the beta-common receptor), which mediates tissue-protective and anti-inflammatory signaling distinct from red-blood-cell production — this selective mechanism is the entire rationale for engineering ARA-290 out of EPO's larger structure in the first place.

Research Context

The cited Phase 2 trial studied ARA-290 in patients with type 2 diabetes and painful neuropathy over a 56-day period, reporting improvements in glycemic control (HbA1c), lipid profiles, and neuropathic symptom severity, alongside increased corneal nerve fiber density in patients with reduced baseline nerve fiber density — a structural, not just symptomatic, finding. Separately, ARA-290 has been studied for neuropathic pain associated with sarcoidosis, and the FDA has granted it Orphan Drug designation for that specific indication.

Regulatory Status

Orphan Drug designation is not the same as approval — it's a status the FDA grants to encourage development of drugs for rare conditions (financial and regulatory incentives), typically awarded well before any efficacy/safety approval decision. As of this writing, ARA-290 remains investigational.

Limitations of the Current Evidence

• The cited trial is a Phase 2 study — moderate scale, not yet the larger confirmatory trials that would typically precede an approval decision.
• Findings are specific to diabetic neuropathy; the sarcoidosis-related neuropathic pain application rests on separate research not detailed in the study cited here.